Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia
Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.
Abhinav Deol, MD, associate clinical professor, Barbara Ann Karmanos Cancer Institute, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.
CAR T-cell therapy is an important modality of treatment for patients with lymphoma and leukemia.
However, patients must demonstrate good performance status, along with good social support to be eligible for treatment, says Deol. As such, CAR T-cell therapy may not be an option for every patient.
Additionally, after patients receive an infusion of CAR T-cell therapy, they must be observed for potential neurological toxicity, hypogammaglobulinemia, and other long-term adverse effects that could require chronic immunoglobulin replacement, Deol says. Moreover, patients may develop cytopenias that can last for up to 1 year following infusion.
The field of lymphoma and leukemia continues to gain experience in administering this therapeutic modality and, in the near future, additional regulatory approvals for the modality are expected, Deol concludes.
